Expertise in
15
conditions

Julia B. Hennermann

Mainz, RP, DE 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
15
conditions
Mainz, RP, DE 
OverviewLocationsClinical Research

Overview

Julia Hennermann practices in Mainz, Germany. Ms. Hennermann is highly rated in 15 conditions, according to our data. Her top areas of expertise are Gaucher Disease Type 3, Alpha Mannosidosis, Fabry Disease, and Phenylketonuria (PKU).

Her clinical research consists of co-authoring 97 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Female

Locations

Mainz, RP, Germany
Other Locations
Gutenberg, RP, Germany
Charité Universitätsmedizin
Berlin, BE, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Natural History Study of Infantile and Juvenile GM1 Gangliosidosis (GM1) Patients
Natural History Study of Infantile and Juvenile GM1 Gangliosidosis (GM1) Patients
Enrollment Status: Recruiting
Publish Date: October 15, 2024
Early Detection of Fabry Disease (FD): Using Real-World Data for the Development of Advanced Natural Language Processing Methods: Retrospective Database Analysis
Early Detection of Fabry Disease (FD): Using Real-World Data for the Development of Advanced Natural Language Processing Methods: Retrospective Database Analysis
Enrollment Status: Active_not_recruiting
Publish Date: September 05, 2025
Intervention Type: Other
A Long-Term, Open-Label, Multicenter, Phase IV Study to Assess Longitudinal Changes on Height and Weight in Patients With MPS II Who Are Receiving Elaprase and Started Treatment With Elaprase at <6 Years of Age
A Long-Term, Open-Label, Multicenter, Phase IV Study to Assess Longitudinal Changes on Height and Weight in Patients With MPS II Who Are Receiving Elaprase and Started Treatment With Elaprase at <6 Years of Age
Enrollment Status: Completed
Publish Date: August 11, 2025
Intervention Type: Drug
Study Drug: Elaprase
Study Phase: Phase 4
Arimoclomol Prospective Double-blind, Randomised, Placebo-controlled Study in Patients Diagnosed With Niemann-Pick Disease Type C
Arimoclomol Prospective Double-blind, Randomised, Placebo-controlled Study in Patients Diagnosed With Niemann-Pick Disease Type C
Enrollment Status: Completed
Publish Date: November 29, 2024
Intervention Type: Drug
Study Drug: Arimoclomol
Study Phase: Phase 2/Phase 3
PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints): A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Efficacy and Safety of Pegzilarginase in Children and Adults With Arginase 1 Deficiency
PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints): A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Efficacy and Safety of Pegzilarginase in Children and Adults With Arginase 1 Deficiency
Enrollment Status: Completed
Publish Date: November 19, 2024
Intervention Type: Drug
Study Drug: PEG-Zilarginase
Study Phase: Phase 3
A Phase 3, Open-label Study to Evaluate the Efficacy and Safety of REPLAGAL® in Treatment-naïve Subjects With Fabry Disease
A Phase 3, Open-label Study to Evaluate the Efficacy and Safety of REPLAGAL® in Treatment-naïve Subjects With Fabry Disease
Enrollment Status: Terminated
Publish Date: June 17, 2024
Intervention Type: Drug
Study Drug: Replagal
Study Phase: Phase 3
MPS VI Clinical Surveillance Program (CSP)
MPS VI Clinical Surveillance Program (CSP)
Enrollment Status: Completed
Publish Date: April 05, 2021
A Phase 1 Safety and Dose-Finding Study of a Human Insulin Receptor Monoclonal Antibody-Human Iduronate 2-Sulfatase (IDS) Fusion Protein, AGT-182 in Adult Patients With Mucopolysaccharidosis II (MPS II, Hunter Syndrome)
A Phase 1 Safety and Dose-Finding Study of a Human Insulin Receptor Monoclonal Antibody-Human Iduronate 2-Sulfatase (IDS) Fusion Protein, AGT-182 in Adult Patients With Mucopolysaccharidosis II (MPS II, Hunter Syndrome)
Enrollment Status: Completed
Publish Date: September 18, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 7 Less Clinical Trials

97 Total Publications

Retinal microstructual and microvascular changes in mucopolysaccharidoses.
Retinal microstructual and microvascular changes in mucopolysaccharidoses.
Journal: Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
Published: April 19, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Hennermann's expertise for a condition
ConditionClose
View All 12 Advanced Conditions
View All 37 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile